Home Newsfeeds Celldex Therapeutics Q3 Sales $407.00K Up From $153.00K YoY

Celldex Therapeutics Q3 Sales $407.00K Up From $153.00K YoY

Celldex Therapeutics (NASDAQ:CLDX) reported $407.00 thousand in sales this quarter. This is a 166.01 percent increase over sales of $153.00 thousand the same period last year.

byBenzinga Newsdesk

November 9, 2022

1 minute read

Celldex Therapeutics (NASDAQ:CLDX) reported $407.00 thousand in sales this quarter. This is a 166.01 percent increase over sales of $153.00 thousand the same period last year.

News

Standard Lithium And Equinor Enters Partnership To Accelerate The Development Of Sustainable Lithium Projects In The Smackover Formation

By Benzinga Newsdesk

May 8, 8:24 AM

Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSXV:SLI) (NYSE:SLI) (FRA:S5L), a leading near-commercial lithium development company, today announced the closing of a landmark strategic partnership (the

EQNR

Lifeist Q1 FY23 Revenue Grows 22.5% YoY, What About Adjusted EBITDA?

By Vuk Zdinjak

April 28, 8:35 AM

Lifeist Wellness Inc. (TSXV:LFST) (FRANKFURT:M5B) (OTCMKTS:LFSWF) net revenue increased 22.5% to CA$5.9 million ($4.3 million) in Q1 2023 compared to CA$4.9 million in Q1 2022. The increase was driven by a CA$515,000, or 16.4%, increase in Canadian cannabis revenue and CA$551,000 contribution from Mikra.

LFSWF